Introduction to Pharmacovigilance and Adverse Drug Reactions
Pharmacovigilance is the science and set of activities concerned with the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems that may arise during the use of pharmaceutical products.
It focuses on the continuous monitoring and evaluation of the safety of marketed drugs, ensuring that any risks associated with medicines are identified and managed appropriately throughout their lifecycle.
Pharmacovigilance includes the systematic collection, documentation, and analysis of data related to adverse drug reactions (ADRs) and other safety concerns, followed by the implementation of appropriate regulatory actions whenever necessary to protect public health.
The history of pharmacovigilance can be traced back to 1848, with the first documented case linked to the death caused by chloroform administration, which highlighted the need for drug safety monitoring and laid the foundation for this field.
One of the primary objectives of pharmacovigilance is the detection of adverse drug reactions (ADRs) associated with drugs that are either already available in the market or still under development, helping identify previously unknown risks.
It involves the assessment of drug safety by collecting and critically analyzing data from multiple sources such as clinical trials, spontaneous reporting systems, published scientific literature, and regulatory submissions, allowing a comprehensive understanding of a drug’s safety profile.
Pharmacovigilance helps in the understanding of risk factors that contribute to the occurrence of adverse drug reactions, including patient-specific characteristics, possible drug-drug interactions, dosage forms, treatment duration, and underlying medical conditions that may influence drug response.
A major goal of pharmacovigilance is the prevention of harm, ensuring that risks associated with medicine use are minimized through timely identification and intervention.
It promotes the rational use of drugs by supporting evidence-based prescribing practices, encouraging the safe and effective use of medicines, and reducing unnecessary or inappropriate drug exposure.
Pharmacovigilance plays a vital role in the communication of safety information to healthcare professionals, patients, and the general public, helping raise awareness about potential risks and encouraging the reporting of adverse effects for improved safety surveillance.
It provides regulatory authorities with essential evidence and safety data needed to make informed decisions regarding drug approval, labeling updates, restrictions of use, risk management strategies, and post-marketing surveillance requirements for pharmaceutical products.
Pharmacovigilance is based on continuous monitoring, which ensures that medicines remain under observation even after approval and market release, allowing for the identification of rare, delayed, or long-term adverse effects that may not have been detected during pre-marketing clinical trials.
The Importance of Drug Safety Monitoring
Pharmacovigilance and drug safety monitoring are essential for the continuous evaluation of the safety and efficacy of drug products even after they have been marketed, as certain adverse effects may only become apparent when medicines are used by larger and more diverse populations over extended periods.
Detection of rare adverse drug reactions (ADRs): Medication errors and adverse drug reactions are extensively documented, and hospital-based surveillance systems play a significant role in reducing both the risk and severity of ADRs. These systems also assist in the identification and documentation of rare adverse reactions that may not have been detected during clinical trials due to limited sample sizes.
Identification of long-term and delayed effects: Drug safety monitoring is important for recognizing adverse effects that develop after prolonged use or appear long after treatment initiation, helping prevent unnecessary or unsafe extended use of medications.
Monitoring drug use in real-world conditions: Pharmacovigilance evaluates how medicines perform outside controlled clinical trial environments by monitoring their actual use in diverse patient populations, ensuring rational drug use and understanding how drugs behave under real-world healthcare conditions through detailed drug profiles.
Detection of drug interactions: Safety monitoring helps identify interactions between multiple medications, especially in patients with chronic diseases or polypharmacy habits, where the use of several drugs simultaneously may lead to reduced therapeutic effectiveness or unexpected adverse effects.
Ensuring safe and rational use of medicines: Regulatory guidance, compliance measures, and evidence-based monitoring support the safe, effective, and rational use of medicines, minimizing misuse, overuse, or inappropriate prescribing practices.
Protection of public health: Drug safety monitoring contributes to public health protection by ensuring patient confidentiality through carefully implemented standard operating procedures (SOPs) and by enabling timely actions such as product recalls, safety alerts, and withdrawal of harmful drugs from the market when risks are identified.
Improvement of risk-benefit assessment: Pharmacovigilance strengthens the process of evaluating whether the therapeutic benefits of a drug outweigh its potential risks by promoting understanding, education, clinical training, and effective communication with the public regarding when drug continuation or discontinuation is appropriate.
Building confidence in healthcare systems: Proper training, transparency, and accountability in drug use and safety monitoring enhance trust in healthcare systems, allowing patients and healthcare professionals to have greater confidence in therapeutic decisions and the healthcare team.
Regulatory decision-making: Drug safety monitoring provides regulatory authorities with transparent and evidence-based information needed to clarify misunderstandings and make informed decisions regarding the benefits, risks, effectiveness, labeling changes, safety warnings, and overall risk management strategies for medicines.
Early detection of safety signals: Pharmacovigilance enables the identification of early warning signs of potential drug-related risks, allowing for prompt intervention, prevention of widespread harm, and timely communication to healthcare professionals, thereby reducing the seriousness and impact of adverse outcomes associated with drug therapy.
Classification of Adverse Drug Reactions
Adverse Drug Reactions (ADRs) are defined as noxious and unintended responses to a drug that occur at doses normally used in humans for the prophylaxis, diagnosis, treatment of diseases, or modification of physiological functions. These reactions may arise due to direct drug toxicity or hypersensitivity reactions, and understanding their classification is essential for effective drug safety monitoring and management.
The Rawlins-Thompson classification of ADRs categorizes adverse drug reactions into six main types: Type A, Type B, Type C, Type D, Type E, and Type F, based on their mechanism, predictability, time of occurrence, and clinical characteristics.
Type A (Augmented Reaction):
The letter “A” stands for Augmented reaction.
Approximately 80% of all adverse drug reactions are Type A reactions, making them the most common category.
These reactions are related to the known pharmacological actions of the drug and are generally predictable.
They are dose-dependent, meaning that an increase in dose usually leads to an increase in the severity of the adverse effect.
These reactions are commonly observed with drugs that have a low therapeutic index or in patients with impaired drug elimination, such as those with renal or hepatic dysfunction.
Prevention and management usually involve dose reduction or adjustment.
Examples include bleeding caused by warfarin and other anticoagulants, hypoglycemia induced by insulin, and bradycardia associated with beta-blockers.
Type B (Bizarre Reaction):
The letter “B” stands for Bizarre reaction.
These reactions are unpredictable, uncommon, and infrequent.
They are characterized by qualitative differences in individual responses to drugs, meaning they do not relate directly to the known pharmacological action of the medicine.
Type B reactions often involve allergic, immunological, or idiosyncratic mechanisms.
Since they are not dose-dependent and cannot usually be predicted, they can be difficult to prevent.
Type C (Chronic Use Reaction):
The letter “C” stands for Chronic drug use reaction.
These reactions are associated with the cumulative toxic effects of a drug over time, where adverse effects gradually develop with prolonged use.
They are generally time-related and dose-related, though they are less common compared to Type A reactions.
Prevention typically involves reducing the dose or limiting the duration of therapy.
An example is hypothalamic-pituitary-adrenal (HPA) axis suppression caused by long-term corticosteroid therapy.
Type D (Delayed Reaction):
The letter “D” stands for Delayed reaction.
These reactions occur after a prolonged period of drug use or even years after treatment exposure.
They result from extended drug exposure and accumulation or limited exposure during a critical period of development, such as pregnancy.
Examples include teratogenic effects of phenytoin during pregnancy and contact dermatitis caused by prolonged metal exposure.
Type E (End of Use Reaction):
The letter “E” stands for End of Use reaction.
These reactions occur when a medicine is abruptly discontinued after prolonged use.
They are commonly referred to as withdrawal reactions.
Symptoms may include insomnia, anxiety, and perceptual disturbances, especially following sudden withdrawal of benzodiazepines.
These reactions can often be prevented through gradual tapering or slow withdrawal of the drug rather than abrupt discontinuation.
Type F (Failure of Therapy Reaction):
The letter “F” stands for Failure of therapy reaction.
This type is characterized by the unexpected failure of a drug to produce its intended therapeutic effect.
It may occur when one drug undesirably increases or decreases the effectiveness of another drug, making it often dose-dependent.
Common causes include drug-drug interactions, counterfeit medications, underdosing, improper patient compliance, and antimicrobial resistance.
Management involves identifying and correcting the underlying cause, such as adjusting doses, addressing interactions, or ensuring medication quality.
Examples include inadequate effectiveness of oral contraceptives when co-administered with enzyme inducers and treatment failure caused by antimicrobial resistance.
Serious vs. Non-Serious Adverse Events
According to the World Health Organization (WHO), adverse effects are defined as “any untoward medical occurrence that may present during treatment with a medicine but which does not necessarily have a causal relationship with this treatment.” This means that an adverse event may occur during drug therapy without definite evidence that the medicine directly caused it.
Adverse events are broadly classified into serious and non-serious adverse events, depending on their severity, clinical consequences, and impact on patient health. While most adverse events are non-serious and manageable, some can be severe enough to result in hospitalization, long-term disability, life-threatening complications, or even death.
Serious Adverse Events (SAEs):
These are adverse events that pose a significant risk to the patient’s health or life.
They often require urgent medical attention, hospitalization, discontinuation of therapy, or immediate regulatory reporting.
Serious adverse events may lead to permanent disability, congenital abnormalities, severe organ damage, or death if not promptly managed.
Non-Serious Adverse Events:
These are adverse events that are generally mild to moderate in severity and usually do not cause long-term harm.
They often result in temporary discomfort or minor clinical symptoms that can usually be managed without discontinuing therapy.
Routine monitoring and standard reporting procedures are generally sufficient for these events.
Nature of Reaction:
Serious adverse events are often associated with unpredictable or immunologic reactions, which occur unexpectedly and may involve abnormal immune responses.
Non-serious adverse events are generally predictable and non-immunologic reactions, often related to the known pharmacological effects of the drug.
Dependence:
Serious adverse events are often patient-dependent, meaning they are influenced by individual factors such as genetics, immune status, age, underlying diseases, or hypersensitivity.
Non-serious adverse events are usually dose-dependent, where the severity increases with higher doses of the drug.
Severity:
Serious adverse events have high clinical severity, often requiring immediate intervention.
Non-serious adverse events are usually low to moderate in severity and can often resolve spontaneously or with minor treatment adjustments.
Outcome:
Serious adverse events may result in hospitalization, significant disability, congenital abnormalities, or death.
Non-serious adverse events usually cause temporary discomfort, minor symptoms, or reversible effects without lasting damage.
Impact on Therapy:
Serious adverse events often require immediate discontinuation of the offending drug and alternative treatment strategies.
Non-serious adverse events are generally manageable through dose adjustment, symptomatic treatment, or continued observation without stopping therapy.
Causes of Serious Adverse Events:
Idiosyncratic reactions or pharmacogenetic variations that cause abnormal responses in certain individuals.
Genetically determined toxicity, where inherited factors influence drug metabolism or sensitivity.
Hypersensitivity reactions, including allergic or immune-mediated responses.
Intolerance or supersensitivity, where even normal doses produce exaggerated harmful effects.
Causes of Non-Serious Adverse Events:
Excessive pharmacological effects resulting from the expected action of the drug.
Dose-dependent toxic effects, where higher doses increase the likelihood of mild adverse reactions.
Rebound responses after discontinuation or drug withdrawal reactions, which occur when a medication is suddenly stopped.
Reporting Requirements:
Serious adverse events require urgent and immediate reporting to regulatory authorities and pharmacovigilance systems to ensure rapid assessment and intervention.
Non-serious adverse events are typically reported through routine pharmacovigilance procedures for continuous safety monitoring.
Examples of Serious Adverse Events:
Drug-induced hearing loss
Severe bleeding caused by anticoagulants
Teratogenic effects caused by phenytoin during pregnancy
Examples of Non-Serious Adverse Events:
Headache
Dizziness
Non-severe skin rash
Other mild and temporary reactions that generally resolve without major clinical consequences.
Spontaneous Reporting Systems (FAERS, Yellow Card, DAEN, Canada Vigilance)
Spontaneous Reporting Systems (SRS) are passive surveillance platforms that allow healthcare professionals, patients, and pharmaceutical companies to report suspected Adverse Drug Reactions (ADRs) to national regulatory authorities. These systems play a central role in pharmacovigilance by enabling the collection of post-marketing safety data from real-world drug use.
Spontaneous reporting is defined as the voluntary communication of suspected adverse drug reactions by a patient, healthcare professional, or pharmaceutical company to the National Pharmacovigilance Program, particularly for adverse effects that were not identified during preclinical studies or clinical trials.
These reporting systems are essential because clinical trials have limitations, such as restricted sample sizes, shorter study durations, and limited population diversity, which may prevent the detection of rare, delayed, or population-specific adverse reactions.
The information collected through spontaneous reporting systems helps in the identification of patterns, safety signals, and emerging concerns related to medicines, allowing regulatory authorities to take timely actions such as issuing safety warnings, updating product labels, restricting use, or withdrawing harmful products from the market.
Different countries operate their own national spontaneous adverse event reporting systems, each designed to monitor medicine safety and support public health protection.
FAERS (FDA Adverse Event Reporting System):
FAERS is the adverse event reporting database maintained by the U.S. Food and Drug Administration (FDA).
It is specifically designed to support the FDA’s post-marketing safety surveillance program for drug products and therapeutic biological products.
This system collects and analyzes reports of adverse events, medication errors, and product quality complaints associated with approved medicines.
FAERS helps the FDA identify potential safety concerns and determine whether regulatory actions are required.
It is also commonly associated with “MedWatch,” which serves as the FDA’s primary reporting program for adverse events and safety information.
Yellow Card Scheme:
The Yellow Card Scheme is the official spontaneous adverse event reporting system in the United Kingdom.
It was established in 1964 following concerns regarding medicine safety.
This platform allows reporting of suspected or observed adverse drug reactions related to medicinal products and medical devices.
The scheme uses a black triangle symbol (▼) to identify medicines that require intensive monitoring, usually newly approved drugs or products with limited long-term safety data.
Information typically included in a Yellow Card report consists of:
Details of the suspected drug
Description of the suspected adverse reaction
Patient details
Reporter information
DAEN (Database of Adverse Event Notifications):
DAEN is Australia’s national database for reporting suspected adverse events related to medicines and therapeutic products.
It provides public access to information regarding reported side effects, promoting transparency in drug safety monitoring.
DAEN is managed by the Therapeutic Goods Administration (TGA), Australia’s regulatory authority for therapeutic products.
It is also commonly referred to as the “Blue Card” ADR reporting system.
This system helps identify trends in adverse event reporting and supports regulatory decision-making regarding medicine safety in Australia.
Canada Vigilance:
Canada Vigilance is the spontaneous adverse reaction reporting program operated by Health Canada.
It is designed to collect reports of suspected adverse reactions associated with health products, including both prescription and non-prescription medicines.
The program supports post-marketing safety surveillance and helps detect new safety concerns related to drugs and other therapeutic products.
Information gathered through Canada Vigilance assists Health Canada in assessing risks and implementing appropriate regulatory actions to protect public health.
Collectively, these spontaneous reporting systems are critical for global pharmacovigilance efforts, enabling continuous drug safety monitoring, early signal detection, and improved patient safety across healthcare systems worldwide.
Signal Detection and Management
A signal in pharmacovigilance refers to information about a new, previously unknown, or incompletely documented adverse reaction of a drug that requires further investigation and assessment to determine its validity and clinical significance.
Signal detection is an essential component of pharmacovigilance because it provides an early warning system for identifying situations where a drug may be causing:
A new adverse effect that has not been previously recognized
A known adverse effect that is becoming more frequent
A known reaction that appears more severe in a specific population or under certain conditions
Signal detection involves identifying unusual patterns, trends, or clusters of adverse event reports that stand out from expected background reporting rates, helping regulatory authorities and healthcare professionals recognize potential safety concerns at an early stage.
There are two main types of signal detection methods: qualitative methods and quantitative methods.
Qualitative Methods:
These methods rely on clinical judgment, spontaneous reporting data, and case-based evaluations to understand why a potential safety risk may exist.
They are particularly useful for identifying rare or unusual adverse events that may not be easily detected through statistical methods.
Qualitative methods include:
Clinical review of Individual Case Safety Reports (ICSRs):
Detailed examination of individual adverse event reports to assess clinical relevance, temporal association, and possible causation.
Case series analysis:
Analysis of multiple similar cases by comparing factors such as drug dose, timing of exposure, onset of adverse effects, and patient outcomes, helping identify common patterns.
Causality assessment:
Evaluation of the likelihood that a specific medicine or vaccine caused the observed adverse event, based on factors such as temporal relationship, dechallenge/rechallenge information, and alternative explanations.
Medical literature review:
Examination of published scientific studies, case reports, and clinical evidence to identify previously documented or emerging adverse reactions.
Quantitative Methods:
These methods use statistical analysis, mathematical models, and data mining techniques to identify unusual drug-event relationships within large datasets.
They are especially valuable for detecting early safety signals from epidemiological studies, spontaneous reporting databases, and ongoing clinical trial data.
Quantitative methods include:
Disproportionality Analysis:
This method compares how frequently a specific drug-event pair appears in a reporting database versus how often such combinations would be expected to occur by chance. A disproportionately high frequency may indicate a potential safety signal.
Proportional Reporting Ratio (PRR):
This measures whether a particular adverse event is reported more frequently with one specific drug compared to all other drugs in the database. A high PRR may suggest an association requiring further investigation.
Reporting Odds Ratio (ROR):
This compares the odds of a particular adverse event occurring with a specific drug versus the odds of the same event occurring with all other drugs, helping assess whether reporting is unusually elevated.
Signal Management is the structured process of handling safety signals from their initial detection through evaluation and final regulatory action.
The purpose of signal management is to ensure that drug safety is continuously monitored, assessed, and acted upon whenever necessary to protect public health.
The major steps involved in Signal Management are:
Signal Detection:
This is the initial step involving the collection of safety data from relevant sources and identification of potential signals.
Safety signals may arise from multiple sources, including:
Spontaneous adverse event reporting systems
Case-control studies
Cohort studies
Preclinical studies
Clinical trials
Published medical literature
Signal Assessment:
In this stage, detected signals undergo qualitative review to determine whether they represent a true safety concern or a false association.
Patterns are carefully analyzed using specialized software, statistical tools, and expert clinical review.
The seriousness and clinical importance of the adverse event are also assessed at this stage.
Signal Evaluation:
The identified signal is further reviewed based on factors such as:
Severity of the adverse event
Frequency of occurrence
Vulnerability of affected populations
Biological plausibility
Based on the evaluation, appropriate actions may include:
Updating product labels
Adding new warnings or precautions
Implementing additional monitoring requirements
Conducting further studies
Decision-Making and Action:
This final stage involves the implementation of regulatory decisions and risk minimization measures.
Actions may include:
Communicating safety information to healthcare professionals and the public
Updating product information
Monitoring follow-up data
Tracking changes in risk over time
Restricting use or withdrawing the product if necessary
Effective signal detection and management are critical for ensuring continuous benefit-risk assessment of medicines, enabling early intervention and safeguarding patient health.
Causality Assessment Methods are systematic approaches used to determine the relationship between a drug, an adverse drug reaction (ADR), and the likelihood that the observed adverse event was actually caused by the suspected medicine. These methods are essential for evaluating drug safety, detecting potential safety signals, supporting regulatory decision-making, and ensuring patient welfare.
Causality assessment helps healthcare professionals and regulatory authorities distinguish whether an adverse event is definitely, probably, possibly, or unlikely related to a drug, rather than resulting from other factors such as underlying disease, concurrent medications, or environmental influences.
One of the most commonly used causality assessment methods is the Naranjo Scale, which was developed in 1991 by Naranjo and coworkers from the University of Toronto.
The Naranjo Scale was specifically designed for use in controlled clinical trials and registration studies of new medications administered at therapeutic doses, making it a standardized and structured method for ADR evaluation.
This method evaluates the likelihood of causation using a series of questions related to:
The timing of the adverse event in relation to drug administration
Improvement of the reaction after drug withdrawal (dechallenge)
Reappearance of the reaction after re-administration of the drug (rechallenge)
The presence of alternative possible causes for the adverse event
Other clinical factors that may support or weaken the suspected relationship
The Naranjo questionnaire consists of 10 questions, and each question is answered as:
Yes
No
Do not know
Each response is assigned a numerical score with point values of:
-1
0
+1
+2
After summing all the points, the adverse drug reaction is classified into one of four probability categories:
Definite ADR: Score ≥ 9
Probable ADR: Score 5–8
Possible ADR: Score 1–4
Doubtful ADR: Score 0 or less
The Naranjo Scale is widely valued because it provides a structured, objective, and reproducible method for assessing suspected adverse drug reactions.
Another highly important causality assessment method is the WHO-UMC method, where WHO-UMC stands for World Health Organization–Uppsala Monitoring Centre.
The WHO-UMC system is widely used in international pharmacovigilance programs and is considered one of the most globally recognized approaches for ADR causality assessment.
This method evaluates causality based on several important clinical considerations, including:
The time relationship between drug use and occurrence of the adverse event
The presence or absence of competing causes, such as disease progression or other medications
The patient’s response to drug withdrawal
Effects observed after dose reduction
The outcome following drug re-administration, if available
The WHO-UMC method categorizes adverse events into six causality categories, each with specific assessment criteria.
Certain:
The event or laboratory abnormality has a plausible time relationship to drug intake
The reaction cannot be explained by disease or other drugs
The response to drug withdrawal is pharmacologically or pathologically plausible
The event is definitive pharmacologically or phenomenologically, such as an objective and recognized pharmacological effect
Rechallenge is satisfactory, if performed and necessary
Probable/Likely:
The event or laboratory abnormality has a reasonable time relationship to drug intake
It is unlikely to be explained by disease or other drugs
The response to withdrawal is clinically reasonable
Rechallenge is not required for this classification
Possible:
The event or laboratory abnormality has a reasonable time relationship to drug administration
It could also be explained by disease or other drugs
Information regarding drug withdrawal may be lacking, incomplete, or unclear
Unlikely:
The event or laboratory abnormality has a timing relationship that makes association with the drug improbable, though not impossible
Other explanations such as disease processes or other medications are more plausible
Conditional/Unclassified:
An event or laboratory abnormality has been reported
Additional data are required for proper assessment, or
Further information is currently under examination
Unassessable/Unclassifiable:
A report suggests an adverse reaction
The event cannot be properly judged because the available information is insufficient or contradictory
The necessary data cannot be supplemented or verified
In the WHO-UMC system, all assessment criteria should be reasonably complied with before assigning a final causality category, ensuring consistency and reliability in evaluation.
These causality assessment methods are essential tools in pharmacovigilance because they support accurate identification of ADRs, improve signal detection, guide regulatory actions, and contribute to safer use of medicines worldwide.
The Role of the Qualified Person for Pharmacovigilance (QPPV)
The Qualified Person for Pharmacovigilance (QPPV) is a key professional responsible for establishing, maintaining, and overseeing the pharmacovigilance system within pharmaceutical companies, clinical settings, and hospitals, ensuring that drug safety is continuously monitored and managed effectively.
A QPPV is typically an individual with a degree in medicine, pharmacy, or another relevant scientific discipline, along with several years of practical experience in drug safety and pharmacovigilance activities, and possesses in-depth knowledge of pharmacovigilance legislation, regulatory requirements, procedures, and international guidelines.
The QPPV serves as a critical link between pharmaceutical organizations and regulatory authorities, facilitating communication and ensuring that all safety-related information about medicinal products is properly reported, evaluated, and acted upon.
This role is central to patient safety, as the QPPV is responsible for identifying, assessing, and managing risks associated with medicinal products, thereby contributing to the safe and rational use of medicines.
The QPPV is responsible for maintaining and overseeing the company’s pharmacovigilance system, ensuring that all activities are properly documented, compliant with regulatory requirements, and functioning effectively.
They ensure timely, complete, and accurate reporting of adverse events to regulatory authorities, including overseeing the collection, evaluation, and submission of Individual Case Safety Reports (ICSRs) in accordance with legal timelines and standards.
The QPPV plays a major role in the development, implementation, maintenance, and evaluation of Risk Management Plans (RMPs), ensuring that identified risks are minimized and that the effectiveness of risk minimization measures is continuously assessed.
They are responsible for the preparation and submission of Periodic Safety Update Reports (PSURs), which provide a comprehensive evaluation of a product’s benefit-risk profile over time, ensuring compliance with regulatory guidelines.
The QPPV oversees and coordinates pharmacovigilance audits and regulatory inspections, ensuring that the organization is inspection-ready at all times and that any identified deficiencies are addressed through Corrective and Preventive Actions (CAPAs).
They are required to stay continuously updated with changes in pharmacovigilance regulations, guidelines, and best practices, ensuring that the organization remains compliant with evolving global regulatory requirements.
The QPPV is also responsible for providing training and guidance to relevant staff, ensuring that all personnel involved in pharmacovigilance activities are aware of reporting requirements, standard operating procedures (SOPs), and documentation practices, and that such training is properly recorded and maintained.
Overall, the QPPV plays a strategic and operational role in ensuring drug safety, regulatory compliance, and protection of public health, making them a cornerstone of modern pharmacovigilance systems.
Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) are important regulatory documents used in pharmacovigilance for the continuous monitoring and evaluation of the safety profile of medicinal products after they have been approved for marketing.
These periodic safety reports are prepared as part of routine pharmacovigilance activities for all medicinal products, with the purpose of ensuring continuous safety monitoring and the implementation of appropriate regulatory actions whenever necessary as part of a pharmacovigilance plan.
They play a significant role in the monitoring of the safety profile of approved products, allowing for ongoing assessment of how medicines perform in real-world clinical use after market authorization.
The reports include activities such as signal detection, which helps identify potential new safety concerns or changes in the frequency or severity of known adverse effects.
They also involve evaluation of safety issues, where identified risks are carefully assessed to determine their significance and potential impact on patient safety.
Another important function of PSUR/PBRER is the updating of product labeling, ensuring that healthcare professionals and patients are provided with the most current safety information, warnings, precautions, and usage recommendations.
These reports support ongoing liaison and communication with regulatory authorities, enabling transparent sharing of safety data and facilitating regulatory decision-making.
PSUR/PBRER reports are prepared and submitted by the Marketing Authorization Holder (MAH) of an approved medicinal product, usually the pharmaceutical company responsible for manufacturing and marketing the medicine.
After a drug receives approval for marketing, pharmaceutical companies are required to submit these safety reports at regular intervals as part of their post-marketing surveillance obligations.
The reports contain comprehensive information regarding:
Adverse drug reactions (ADRs) reported during the reporting period
Risk-benefit evaluation of the medicinal product
New safety information identified since the previous reporting period
Regulatory actions taken or proposed in response to safety findings
These reports help regulatory authorities assess whether a drug should continue to remain available in the market or whether further action is required, such as label modifications, additional monitoring, restrictions of use, or product withdrawal if necessary.
Both PSUR and PBRER follow standardized structures defined by the International Council for Harmonisation (ICH), ensuring consistency in the format and content of safety reporting across different regulatory regions.
These reports must be submitted according to regulatory-defined schedules and fixed deadlines, which are established by health authorities to ensure timely and systematic review of product safety data.
Overall, PSUR/PBRER reports are essential tools in pharmacovigilance because they support continuous benefit-risk assessment, regulatory oversight, and the protection of public health through ongoing evaluation of medicine safety and effectiveness.
Global Harmonization (ICH E2 Guidelines)
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) developed the E2 series of guidelines to establish internationally accepted standards for the reporting, assessment, and management of drug safety information throughout the lifecycle of medicinal products.
These guidelines play a critical role in promoting global harmonization of pharmacovigilance practices, ensuring consistency in drug safety monitoring, adverse event reporting, and regulatory compliance across different countries and regulatory authorities.
The ICH E2 guideline series helps pharmaceutical companies and regulatory agencies follow standardized procedures for collecting, evaluating, and communicating safety information, thereby improving patient safety and facilitating efficient regulatory decision-making worldwide.
The ICH E2 guideline series is subdivided into several sections, each addressing specific aspects of pharmacovigilance and drug safety reporting.
ICH E2A
ICH E2A defines the standards for the management and reporting of adverse drug reactions (ADRs) during clinical development.
It provides guidance on the identification and classification of adverse events and establishes timelines for expedited reporting of serious and unexpected adverse drug reactions during clinical trials to ensure prompt regulatory communication.
ICH E2B (R2) and ICH E2B (R3)
These guidelines focus on the electronic transmission of Individual Case Safety Reports (ICSRs).
They establish standardized data fields, message formats, and technical requirements for the electronic submission of safety reports from pharmaceutical companies to regulatory authorities.
Their purpose is to ensure efficient, accurate, and globally consistent exchange of safety information.
ICH E2C
ICH E2C provides guidance for the preparation and submission of Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs).
It ensures the periodic evaluation of the benefit-risk profile of marketed medicinal products.
These reports are used to assess emerging risks, newly identified safety concerns, and overall product safety after regulatory approval.
ICH E2D
ICH E2D establishes post-approval safety reporting standards, particularly for accelerated safety communication.
It aligns global timelines for reporting serious and unexpected adverse reactions after a drug has been approved for marketing.
This guideline supports timely communication of critical safety information to regulatory authorities.
ICH E2E
ICH E2E focuses on pharmacovigilance planning.
It provides guidance for developing structured plans to identify, evaluate, monitor, and manage both identified and potential risks associated with medicinal products.
This guideline supports proactive safety monitoring and risk management throughout the post-marketing phase.
ICH E2F
ICH E2F provides a framework for preparing annual safety updates for investigational drugs.
The main focus of this guideline is the integration and analysis of safety data collected from interventional clinical trials involving investigational drugs and biological products that are still under development.
It ensures continuous evaluation of investigational product safety during the clinical research process.
Collectively, the ICH E2 guidelines provide a globally harmonized framework for pharmacovigilance, helping ensure standardized drug safety reporting, regulatory consistency, and effective protection of public health worldwide.
Conclusion
Pharmacovigilance plays a crucial role in the early detection of adverse drug effects, which ultimately contributes to improved patient safety, increased confidence in medications, facilitation of drug development, and optimization of drug therapy through the reduction of medication errors.
Through the continuous collection, monitoring, and analysis of drug safety data, pharmacovigilance helps prevent patient harm, miscommunication, poor clinical decision-making, and breaches of patient confidentiality, thereby strengthening overall healthcare quality and safety systems.
Continuous monitoring of Adverse Drug Reactions (ADRs) enables the identification of rare, serious, delayed, and long-term adverse effects that may not have been detected during preclinical studies or clinical trials.
Signal detection and signal assessment are among the most critical components of pharmacovigilance, as they allow for the early recognition and evaluation of potential safety concerns associated with medicinal products.
Various scientific and regulatory methods are used for detecting safety signals, identifying risks, and managing drug-related hazards, including established causality assessment tools such as the Naranjo Scale and internationally harmonized frameworks such as the ICH E2 guidelines.
These tools and guidelines support the systematic evaluation of adverse events, consistent safety reporting, effective risk communication, and evidence-based regulatory decision-making.
Pharmacovigilance promotes a proactive approach to medicine safety monitoring, ensuring that potential risks are identified and managed before they result in widespread harm to patients.
It also reinforces a culture of continuous patient protection throughout the entire lifecycle of a medicinal product, from clinical development and regulatory approval to post-marketing surveillance.
Overall, pharmacovigilance is essential for maintaining a favorable risk-benefit balance of medicines, ensuring that therapeutic benefits continue to outweigh potential risks while supporting the safe and rational use of drugs in healthcare practice.
References
Fornasier, G., Francescon, S., Leone, R., & Baldo, P. (2018). An historical overview of pharmacovigilance. International Journal of Clinical Pharmacy, 40(4), 744–747. https://doi.org/10.1007/s11096-018-0657-1
Yartsev, A. (2023, December 18). Classification of adverse drug reactions. Deranged Physiology. Retrieved from https://derangedphysiology.com/main/cicm-primary-exam/variability-drug-response/Chapter-320/classification-adverse-drug-reactions
International Council for Harmonisation (ICH). (2004). ICH harmonised tripartite guideline: Pharmacovigilance planning (E2E). Retrieved from https://database.ich.org/sites/default/files/E2E_Guideline.pdf
Oludaiye, O., Oludaiye, M., Williams, B., & Asante, G. (2018, April 18). Pharmacovigilance and safety monitoring. Retrieved from https://www.researchgate.net/publication/391400260_Pharmacovigilance_and_Safety_Monitoring
World Health Organization (WHO). (2002). The importance of pharmacovigilance: Safety monitoring of medicinal products. Retrieved from https://iris.who.int/server/api/core/bitstreams/002b78d5-4dfc-433c-a518-f92ebdee8706/content
Martin, J. H., & Lucas, C. (2021). Reporting adverse drug events to the Therapeutic Goods Administration. Australian Prescriber, 44(1), 2–3. https://doi.org/10.18773/austprescr.2020.077
Health Canada. (2008, January 24). Canada Vigilance Program. Retrieved from https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/canada-vigilance-program.html
U.S. Food and Drug Administration (FDA). (2014). FDA Adverse Event Reporting System (FAERS). Retrieved from https://open.fda.gov/data/faers/
Kumar, A., & Khan, H. (2015). Signal detection and their assessment in pharmacovigilance. Open Pharmaceutical Sciences Journal, 2(1). https://doi.org/10.2174/1874844901502010066
%20Formation,%20Delivery%20Mechanism,%20Microfluidic%20Mixing%20&%20Therapeutic%20Applications.png)
